Sumanta K. Pal
YOU?
Author Swipe
View article: Supplementary table 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Supplementary table 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer Open
Supplementary table 1
View article: Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer Open
Supplementary Data
View article: Supplementary table 2 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Supplementary table 2 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer Open
Supplementary table 2
View article: Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study Open
Although it is an uncommon and not standard strategy, previous ICI in nonmetastatic UC and a period of ≥12 months after previous ICI in the metastatic setting were associated with better outcomes after ICI rechallenge in patients with aUC.
View article: CNT as a robust delivery vehicle for anti-breast cancer drugs: A combined DFT and in-silico study
CNT as a robust delivery vehicle for anti-breast cancer drugs: A combined DFT and in-silico study Open
Nanomedicine has transformed cancer therapy by introducing and developing nanocarriers to enhance drug delivery. Herein, we have executed a computational investigation of the efficiency of two anti-breast cancer drugs viz. Exemestane (EXE)…
View article: 450 Outcomes of immune-checkpoint inhibitors rechallenge in metastatic clear cell renal cell carcinoma: results from a global real-world evidence study
450 Outcomes of immune-checkpoint inhibitors rechallenge in metastatic clear cell renal cell carcinoma: results from a global real-world evidence study Open
View article: Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer
Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer Open
Introduction: Staging inaccuracies in muscle-invasive bladder cancer (MIBC) can lead to undertreatment or overtreatment. We evaluated clinical and pathological predictors of pathologic upstaging (pUS) stratifying by neoadjuvant chemotherap…
View article: Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma Open
Antibody-drug conjugates (ADCs) are revolutionizing the treatment landscape of advanced urothelial carcinoma (aUC). We systematically reviewed the PubMed and Embase databases for published clinical trials evaluating ADC-combination regimen…
View article: 44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)
44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC) Open
Background Tivo is a potent and highly selective VEGFR inhibitor designed to optimize VEGF blockade and minimize off-target toxicities. In TiNivo-2, patients with mRCC who had previous exposure to ICI, were randomized to receive study trea…
View article: 9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)
9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC) Open
Background ccRCC is frequently driven by VHL loss, leading to HIF-2α stabilization and upregulation of downstream targets such as carbonic anhydrase 9 (CA9). While CA9 is a well-established diagnostic marker of HIF pathway activation, its …
View article: 59Real-World efficacy and safety of belzutifan in sporadic metastatic renal cell carcinoma: a multicenter study from the city of hope enterprise
59Real-World efficacy and safety of belzutifan in sporadic metastatic renal cell carcinoma: a multicenter study from the city of hope enterprise Open
Background Belzutifan is a novel HIF-2α inhibitor approved for use in Von Hippel-Lindau (VHL)-associated tumors and sporadic clear cell metastatic renal cell carcinoma (mRCC) following prior treatment with immune checkpoint inhibitor (IO) …
View article: 6Lower checkpoint gene expression is associated with primary resistance to nivolumab-ipilimumab combination in advanced renal cell carcinoma
6Lower checkpoint gene expression is associated with primary resistance to nivolumab-ipilimumab combination in advanced renal cell carcinoma Open
Background Immunotherapy combinations have emerged as the standard of care for patients with advanced renal cell carcinoma (RCC). While the combination of first-line (1 L) nivolumab and ipilimumab has demonstrated long-term durability with…
View article: 50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study
50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study Open
Background Immune checkpoint inhibitor (ICI)-based regimens, represent the current standard of care for first line (1 L) metastatic renal cell carcinoma (mRCC). A subset of patients (pts) experience progressive disease (PD) on first restag…
View article: 27Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma
27Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma Open
Background Errors in alternative splicing (AS) events are recognized as contributors to the tumorigenesis and metastasis of various cancer types. However, the role of aberrant AS events in metastatic renal cell carcinoma (mRCC) remains lar…
View article: 71Educational video intervention to enhance latinx participation in genitourinary oncology clinical trials: a randomized study
71Educational video intervention to enhance latinx participation in genitourinary oncology clinical trials: a randomized study Open
Background The Hispanic and Latinx population comprises over 60 million individuals in the United States, representing approximately 18 percent of the total population. Cancer is the leading cause of death in this group. Despite the diseas…
View article: 11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis
11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis Open
Background Understanding how health-related quality of life (HRQOL) concerns vary by disease stage is essential for developing patient-reported outcome measures (PROMs) that reflect the lived experiences of individuals with renal cell carc…
View article: 26Subgroup analysis of the efficacy and safety of cabozantinib ± atezolizumab in patients from CONTACT-03 who received first-line treatment with immuno-oncology–based combinations
26Subgroup analysis of the efficacy and safety of cabozantinib ± atezolizumab in patients from CONTACT-03 who received first-line treatment with immuno-oncology–based combinations Open
Background Cabozantinib, a tyrosine kinase inhibitor (TKI) that targets multiple kinases, including vascular endothelial growth factor receptor, is a preferred treatment option for patients with previously treated advanced renal cell carci…
View article: 15Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials
15Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials Open
Background Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC subtype, yet prospective evidence guiding first-line systemic therapy remains limited. The phase 2 PAPMET trial in molecularly unselected pRCC and the p…
View article: CABOSEQ 3—Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
CABOSEQ 3—Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Open
These data provide real-world evidence supporting cabozantinib as a second-line treatment option in mRCC following 1L nivolumab-ipilimumab.
View article: IUC24428-85 Real-world effectiveness of ipilimumab plus nivolumab in second-line in patients with metastatic clear cell renal cell carcinoma (mccRCC) based on prior receipt of PD-1/L1 inhibitors
IUC24428-85 Real-world effectiveness of ipilimumab plus nivolumab in second-line in patients with metastatic clear cell renal cell carcinoma (mccRCC) based on prior receipt of PD-1/L1 inhibitors Open
Background Previous phase 3 studies have established that the addition of PD-1/L1 inhibitors (PD-1/L1i) to a tyrosine kinase inhibitor (TKI) after progression on prior anti-PD-1/L1 therapy does not yield additional benefit over single-agen…
View article: Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma Open
We successfully developed item subsets of the FKSI-23 questionnaire that address the multifaceted impact of localized and metastatic RCC on patients' HRQOL. These two clinical settings required distinct tools for optimal measurement of HRQ…
View article: Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma Open
Renal cell carcinoma with sarcomatoid features (sRCC) is a highly aggressive tumor type yet preferentially responds to immune checkpoint blockade (ICB). To better understand microenvironmental mediators of this paradoxical immune sensitivi…
View article: Examining Adherence to ASCO's Language of Respect in Urothelial Carcinoma Research
Examining Adherence to ASCO's Language of Respect in Urothelial Carcinoma Research Open
PURPOSE The ASCO Language of Respect (LoR) guidelines were developed to promote patient-centered language in scientific abstracts and presentations. Herein, we aimed to assess guideline compliance among urothelial carcinoma (UC) abstracts …
View article: Microbiome Modulation for the Treatment of Solid Neoplasms
Microbiome Modulation for the Treatment of Solid Neoplasms Open
The interplay between the human gut microbiome and the immune system has sparked growing interest in microbiome modulation as a therapeutic strategy in oncology. Preclinical studies have identified specific bacterial species linked to impr…
View article: Direct measurement of the $$^{39}$$Ar half-life from 3.4 years of data with the DEAP-3600 detector
Direct measurement of the $$^{39}$$Ar half-life from 3.4 years of data with the DEAP-3600 detector Open
The half-life of $$^{39}$$ Ar is measured using the DEAP-3600 detector located 2 km underground at SNOLAB. Between 2016 and 2020, DEAP-3600 used a target mass of (3269 ± 24) kg of liquid argon distilled from the atmosphere in a direct-d…
View article: Distress and Emotional Support Needs of Patients With Stage IV Cancer and Their Partners: A Biopsychosocial Assessment
Distress and Emotional Support Needs of Patients With Stage IV Cancer and Their Partners: A Biopsychosocial Assessment Open
Background Cancer diagnosis, particularly at advanced stages, affects both patients and their primary caregivers, often resulting in emotional distress. Aims To assess and compare distress levels in patients newly diagnosed with stage IV c…
View article: Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer
Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer Open
Introduction: Prostate cancer has been generally resistant to immunotherapy approaches. Radiation can be immunostimulatory, but the extent to which standard prostate cancer treatments induce immune activation has not been well described. T…
View article: Data from A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
Data from A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma Open
Purpose:Mutations or silencing of the von Hippel–Lindau tumor suppressor gene accumulate hypoxia-inducible factors (HIF). HIF-2α is implicated in the oncogenesis of ∼50% of patients with clear-cell renal cell carcinoma (ccRCC) but has been…
View article: Supplementary Figure S2 from A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
Supplementary Figure S2 from A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure S2. Comparison of percentage changes in patients’ plasma levels of erythropoietin between baseline and cycle 3 day 1 (A) with respect to their BOR and (B) against the change in hemoglobin levels. Statistical comparison…
View article: Supplementary Methods S1 from A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
Supplementary Methods S1 from A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma Open
Key inclusion and exclusion criteria